An early-stage venture capital firm, headquartered in the U.S., allocates roughly 40% of its investments to life sciences. The firm primarily invests from the Seed stage, with the ability to provide follow-on capital. Check sizes are flexible, typically reaching up to mid-6 figures. The firm is open to evaluating opportunities from global companies. 

The firm has broad interests in life sciences and healthcare sectors and considers all types of innovative technologies and indication/disease areas.  
 
The firm does not impose specific requirements on company structure or management teams. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

An investment holding company founded by leading European institutions has raised over €100 million from a base of more than 200 institutional and private shareholders. The firm invests from Seed to Series B stages, with a strong preference for early-stage companies and potential for follow-on funding. Check sizes can reach up to $2 million per company, with flexibility based on the stage of development. The firm is open to both leading and co-investing, and while it is primarily Europe-focused, it is increasingly pursuing U.S. opportunities. 

The firm invests across biotech, MedTech (including therapeutics, medical devices, and diagnostics), and digital health. It remains modality- and indication-agnostic, seeking opportunities with strong growth potential and technological innovation. 

There are no specific requirements for company founding teams, and the firm works closely with its portfolio companies to support their development. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

A global manufacturing company, with over a century of history, is a leader in advanced materials and pressure-sensitive adhesive technologies. With a strong presence in the U.S. for many decades, it has built a reputation for innovation across industries including aerospace, electronics, healthcare, automotive, housing/construction, environmental applications, and general industry. 

In healthcare, the firm is actively seeking strategic partnerships with early-stage companies that complement its product lines. While it is open to meeting startups at the Series A stage, its focus is more on the development stage of technologies rather than funding rounds. The company has a global outlook and welcomes partnerships worldwide. 
 
The company is particularly interested in medical devices and digital health solutions. Priority technologies include sensors for applications such as injury prevention, rehabilitation for musculoskeletal disorders, stroke recovery, and neurological conditions. The company favors startups with prototypes and looks for technologies aligned with its existing products, such as flexible or stress sensors. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

A venture capital firm headquartered in the U.S. invests in pre-seed, seed, and opportunistic Series A tech-bio startups across the country. With access to a strong healthcare and life sciences network, the firm connects portfolio companies with strategic partners and resources to accelerate growth. Initial checks typically range from $300K to $1M, often through syndication or co-investment. 

The firm focuses on technology-driven biotechnology companies, particularly those leveraging AI, computational biology, and machine learning to achieve breakthroughs in drug development, diagnostics, precision medicine, and other healthcare innovations. It is indication-agnostic and prioritizes startups where technology forms the core of the value proposition and enables scalable impact. 

The firm does not enforce rigid requirements on company structure or team experience, instead seeking strong technical foundations, visionary leadership, and a clear path to commercialization. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

A venture capital firm invests in transformative mental health deep tech, including psychedelics and neurotechnology. The firm invests in Pre-Seed, Seed, and Series A companies, aiming to bridge the Series A funding gap and democratize access to frontier modalities at scale. Typical initial investments range from $250,000 to $2 million, with the possibility of follow-on funding. The firm is open to both leading and co-investing in deals, and may take board seats or observer roles on a case-by-case basis. It maintains a global investment scope and is not limited to opportunities within the U.S. 

The firm focuses on transformative technologies that address mental health challenges. Areas of particular interest include psychedelic medicines, especially non-hallucinogenic neuroplastogens (notably NCEs), and short-duration psychedelic compounds aligned with the Spravato medical model. It also invests in digital therapeutics and neurotechnology designed for mental health applications. While the firm is open to early-phase companies, it has a preference for those with strong IP and patent portfolios. It looks for innovations that can make a significant impact on mental health treatments and patient outcomes and places a strong emphasis on ethical conduct. 

The firm does not have strict requirements for founding teams. Its management team, composed of startup founders and operators, provides extensive support to portfolio companies. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

A venture capital firm based in North America focuses on making primarily Seed-stage investments but maintains flexibility to invest from Pre-Seed through Series A. It typically writes first checks ranging from USD 100,000 to USD 1 million, with a sweet spot around USD 500,000, and is open to follow-on participation. The firm has a flexible capital structure and can invest via equity, SAFEs, convertible notes, or other early-stage instruments. It is comfortable acting as lead, co-lead, or syndicate participant, and generally makes 6-10 new investments per year. While its geographic focus is North America, the firm is open to global opportunities where companies are looking to expand into the U.S. market. 

The firm invests primarily in digital health companies and selectively in diagnostics and medical devices, particularly those with significant data value or differentiated data-driven technologies. Within digital health, the firm looks broadly at software and AI-enabled solutions. It is also interested in biotech platform technologies, particularly those enabling delivery or translational efficiency, but tends to avoid single-asset drug candidates. In medtech, the firm is open to all device classifications but shows stronger interest in technologies with clear regulatory or technical differentiation, rather than lightly regulated tools. 

A key focus for the firm is the founding team. Team quality is one of the most important decision-making factors, and the firm evaluates teams holistically, including personality, market fit, experience, and leadership traits. The firm prefers to back experienced and well-rounded teams with a clear execution edge. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

A venture capital firm backed by a major global financial services group actively invests across multiple sectors, including life sciences. The firm typically invests USD 1–2 million per round, though it is capable of larger allocations depending on the opportunity. While globally active, the firm focuses on opportunities with strong relevance to specific market needs in Asia. 

In the life sciences space, the firm is currently targeting therapeutic and medtech products that address major unmet medical needs in its home market. It favors companies with a clear strategy to collaborate with regional pharmaceutical partners, whether through licensing, co-development, or strategic equity participation. The firm considers a range of therapeutic modalities including small molecules, biologics, biosimilars, and reformulated drugs. It primarily seeks products in Phase I clinical trials but may also invest in assets within one year of entering the clinic. Indications of strong interest include oncology and orphan diseases. 

The firm only co-invests in opportunities outside of its home country and strongly prefers that a reputable institutional lead or established syndicate be in place before participating. As such, it tends to evaluate international deals with a co-investment mindset alongside other institutional investors. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.